# Absci Corp (ABSI) — capital_raise/public_offering [announced]
Source: SEC API (secapi.ai) · situation sit_a65400f882d3b6b5b765 · retrieved 2026-08-14T01:43:34.088Z

## Overview
Absci Corporation is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, with a lead program ABS-201 (anti-prolactin receptor antibody) in Phase 1/2a trials for pattern hair loss and endometriosis.

Absci Corporation completed a $100 million underwritten public offering in June 2026, which included a $40 million strategic equity investment from Eli Lilly & Company. The offering also included participation from leading financial institutions including Adage Capital, BVF Partners, Columbia Threadneedle, Invus, Redmile, and a large investment management firm. The net proceeds of $93.6 million from the offering increased Absci's cash, cash equivalents, and marketable securities to $201.1 million as of June 30, 2026, sufficient to fund operations into the second half of 2028.

## Terms
- Counterparty: Eli Lilly & Company and other financial institutions · Deal value: $100.0M · Consideration: mixed

## Key dates
- Announced 2026-08-11

## Timeline
- 2026-08-11 · 8-K (0001672688-26-000134): 8-K - Absci Corp — *Absci Corporation is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, with a lead program ABS-201 (anti-prolactin receptor antibody) in Phase 1/2a trials for pattern hair loss and endometriosis.* Absci Corporation completed a $100 million underwritten public offering in June 2026, which included a $40 million strategic equity investment from Eli Lilly & Company. The offering also included participation from leading financial institutions including Adage Capital, BVF Partners, Columbia Threadneedle, Invus, Redmile, and a large investment management firm. The net proceeds of $93.6 million from the offering increased Absci's cash, cash equivalents, and marketable securities to $201.1 million as of June 30, 2026, sufficient to fund operations into the second half of 2028.
  https://www.sec.gov/Archives/edgar/data/1672688/0001672688-26-000134.txt

## Citations
- 0001672688-26-000134 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000167268826000134